Drug intelligence / Profile preview

recombinant respiratory syncytial virus vaccine

Development stage: Phase 3
Lead developer: MAXVAX Biotechnology
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The recombinant respiratory syncytial virus vaccine is a biological product developed by MAXVAX Biotechnology Limited Liability Company. It is designed to evaluate its safety and immunogenicity in healthy adults aged 18 years and above. The vaccine is administered intramuscularly and is produced using CHO cells.

Other names: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

Beyond the preview

Go deeper on recombinant respiratory syncytial virus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant respiratory syncytial virus vaccine.

Explore the full profile